Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna.Merck has agreed to purchase $50 million of Personalis common stock in a private placement at a price of $3.56 per share, which was the last reported closing price of Personalis’ common stock as reported on The Nasdaq Global Market on December 18, 2024. Following the closing, Merck will own approximately 14 million shares of Personalis common stock, representing an approximately 16.5 percent beneficial ownership interest in Personal
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis, Inc. (NASDAQ: PSNL) had its price target raised by analysts at HC Wainwright from $9.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.25 price target on the stock.MarketBeat
- Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna [Yahoo! Finance]Yahoo! Finance
- Personalis and Tempus Expand Collaboration to Biopharma [Yahoo! Finance]Yahoo! Finance
- Personalis and Tempus Expand Collaboration to BiopharmaBusiness Wire
PSNL
Earnings
- 11/6/24 - Miss
PSNL
Sec Filings
- 12/19/24 - Form 8-K
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- PSNL's page on the SEC website